At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AUPH Aurinia Pharmaceuticals
Market Closed 08-07 16:00:00 EDT
15.85
-0.28
-1.74%
盘后15.80
-0.05-0.33%
19:51 EDT
High16.59Low15.60Vol1.55M
Open16.26D1 Closing16.13Amplitude6.14%
Mkt Cap2.04BTradable Cap2.00BTotal Shares128.60M
T/O24.55MT/O Rate1.23%Tradable Shares126.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Aurinia Pharmaceuticals is Maintained at Sector Perform by RBC Capital
Dow Jones  ·  08-08 02:42
Aurinia Pharmaceuticals is Maintained at Sector Perform by RBC Capital
RBC Adjusts PT on Aurinia Pharmaceuticals to $16 From $15, Keeps Sector Perform Speculative Risk Rating
MT Newswires Live  ·  08-07 20:13
RBC Adjusts PT on Aurinia Pharmaceuticals to $16 From $15, Keeps Sector Perform Speculative Risk Rating
Analysts’ Opinions Are Mixed on These Healthcare Stocks: VistaGen Therapeutics (VTGN), Iovance Biotherapeutics (IOVA) and Aurinia Pharmaceuticals (AUPH)
TIPRANKS  ·  08-06 23:50
Analysts’ Opinions Are Mixed on These Healthcare Stocks: VistaGen Therapeutics (VTGN), Iovance Biotherapeutics (IOVA) and Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate
Benzinga Earnings  ·  08-06 20:40
Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate
Aurinia Publishes Corporate Presentation Outlining Lupkynis Growth Strategy, Aritinercept Development Plans
Reuters  ·  08-06 20:28
Aurinia Publishes Corporate Presentation Outlining Lupkynis Growth Strategy, Aritinercept Development Plans
Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Reuters  ·  08-06 20:13
Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals sees FY26 revenue $315M-$325M, consensus $325.82M
TIPRANKS  ·  08-06 20:12
Aurinia Pharmaceuticals sees FY26 revenue $315M-$325M, consensus $325.82M
Aurinia Q2 Net Income Climbs 74% to $37.4 Million; Revenue Rises 19% to $83.2 Million
Reuters  ·  08-06 20:08
Aurinia Q2 Net Income Climbs 74% to $37.4 Million; Revenue Rises 19% to $83.2 Million
Aurinia Pharmaceuticals Q2 Product Revenue USD 79.412 Million
THOMSON REUTERS  ·  08-06 20:00
Aurinia Pharmaceuticals Q2 Product Revenue USD 79.412 Million
Press Release: Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Dow Jones  ·  08-06 20:00
Press Release: Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap Despite Its 50% Gain
Simply Wall St.  ·  08-04
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap Despite Its 50% Gain
Aurinia Pharmaceuticals Inc Expected to Post Earnings of 24 Cents a Share - Earnings Preview
Reuters  ·  07-27
Aurinia Pharmaceuticals Inc Expected to Post Earnings of 24 Cents a Share - Earnings Preview
New LUPKYNIS Combo Study in Lupus Nephritis Might Change The Case For Investing In Aurinia (AUPH)
Simply Wall St.  ·  07-19
New LUPKYNIS Combo Study in Lupus Nephritis Might Change The Case For Investing In Aurinia (AUPH)
TD Cowen Reaffirms Their Buy Rating on Aurinia Pharmaceuticals (AUPH)
TIPRANKS  ·  07-07
TD Cowen Reaffirms Their Buy Rating on Aurinia Pharmaceuticals (AUPH)
Aurinia Pharmaceuticals Initiates Phase 4 PRESERVE Study in Lupus Nephritis Combination Therapy
MT Newswires Live  ·  07-06
Aurinia Pharmaceuticals Initiates Phase 4 PRESERVE Study in Lupus Nephritis Combination Therapy
Aurinia Pharmaceuticals announces initiation of PRESERVE study
TIPRANKS  ·  07-06
Aurinia Pharmaceuticals announces initiation of PRESERVE study
Aurinia Pharmaceuticals Posts Corporate Presentation on Lupkynis Growth, Autoimmune Disease Pipeline Focus
Reuters  ·  07-06
Aurinia Pharmaceuticals Posts Corporate Presentation on Lupkynis Growth, Autoimmune Disease Pipeline Focus
Aurinia Pharmaceuticals Announces Press Release Availability
Reuters  ·  07-06
Aurinia Pharmaceuticals Announces Press Release Availability
13D Filings -- Barrons.com
Dow Jones  ·  06-13
13D Filings -- Barrons.com
Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook
Simply Wall St.  ·  06-07
Aurinia Data At EULAR 2026 And Insider Buys Shape LUPKYNIS Outlook

Introduction

Company Name.
Aurinia Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Issue price:
--